Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom CEO Buys $97K Worth of Co.'s Stock This Month As Shares Rally

NEW YORK (GenomeWeb News) - Sequenom CEO Harry Stylli bought 13,313 shares of the company's stock at an average price of $1.86 per share for total proceeds of $24,964 on Aug. 11, according to documents filed with the Securities and Exchange Commission.
 
Since Aug. 7, he purchased 53,700 shares for total proceeds of $96,565. He currently owns 54,700 shares of Sequenom stock.
 
Shares in Sequenom were up 5 percent, or $.10, to $1.95 in mid-afternoon trading today. The shares are up 15 percent since Aug. 7, when Stylli began buying the stock.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.